Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc ACHFF


Primary Symbol: V.ARCH

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.


TSXV:ARCH - Post by User

Post by Viking2233on Apr 02, 2024 7:43am
149 Views
Post# 35964496

3 more sites

3 more sitesGood newd continues to flow in here. 3 more sites in Turkey now dosing. My best guess the original 3 sites have already dosed about 15 people.

I would suggest that the new sites would not have been added if initial dosing results were negative so I see this as a very bullish sign

We have one site in Calgary coming on line soon, it would be nice to see one of the major heart hospitals in Toronto or Montreal to join the trial.

It has been over two weeks since Arch released data from published British 3rd party peer review from lung data phase 2 trial. Remember Raymond James analyst was waiting 2 years for this yet not a word from this analyst, plus the company has started a new phase 2 AKI study with 6 locations in Turkey and 1 in Canada. We are also now dosing at a much higher strength. We are going to start another phase 2 trial in the fall with a re-purposed drug that is already proven safe. Again no comment from RJ Analyst.

I wonder if this analyst is even covering Arch anymore????


<< Previous
Bullboard Posts
Next >>